For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
REGULATORY
Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
Health Minister Norihisa Tamura said on August 31 that he plans to confer with a council about resuming the active recommendation of HPV vaccines once the workloads of municipalities associated with COVID-19 subside. Eight years have passed since the Ministry…
To read the full story
Related Article
- MSD Says to Ensure HPV Vaccine Supply in Japan, 4 Million-Plus Syringes for FY2022
March 30, 2022
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
- Japan Panel OKs HPV “Catch-Up” Shots for Females Born in FY1997-FY2005
December 24, 2021
- MSD Japan Hails Resumption of HPV Vaccine Recommendation
November 29, 2021
- Japan Panel Agrees to Give Free “Catch-Up” HPV Shots
November 16, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- Japan to Reinstate HPV Vaccine Recommendation after 8 Years in Limbo
November 15, 2021
- MHLW Health Service Chief Wants Prompt Debate on HPV Recommendation
October 20, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
- LDP League Hails Start of Panel Discussions on HPV Vaccine Recommendation
October 13, 2021
- No Factor to Impede Reinstatement of HPV Vaccine Recommendation: Panels
October 4, 2021
- MHLW Panel to Discuss HPV Vaccine Recommendation on Oct. 1
September 29, 2021
- Japan to Start Discussions in October on Reinstating HPV Vaccine Recommendation
September 21, 2021
- Regional Governors Club Urges Early Conclusion on HPV Vaccines
September 10, 2021
- Plaintiffs of HPV Vaccine Suits Urge MHLW Not to Reinstate Recommendation
September 6, 2021
- MSD Urges Govt to Start HPV Vaccine Discussions as Soon as Possible
September 2, 2021
- Govt Recognizes Need to Resume HPV Vaccine Discussion: Health Minister
August 31, 2021
- Govt Not Planning to Resume Active HPV Vaccine Recommendation before October: Minister
August 30, 2021
- Reinstate Active HPV Vaccine Promotion before October: LDP League
August 27, 2021
- Plaintiffs of HPV Vaccine Suits Urge LDP Group to Hear Stories of Sufferers
April 16, 2021
- LDP League Submits Request to Reinstate HPV Vaccine Promotion
March 30, 2021
- LDP Group to Submit Request for HPV Vaccine Promotion Resumption
March 26, 2021
- Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
July 22, 2020
REGULATORY
- MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
- Japan to Require Drug Makers to Set Up Legal Post of “Stable Supply Manager”
November 29, 2024
- Japan Set to Put Up 100 Billion Yen to Support Pharma under Economic Package
November 29, 2024
- Orphan Tag Given to Renalys’ IgA Nephropathy Therapy and 13 More Drugs
November 29, 2024
- Scrap Off-Year Price Revisions, Smaller Japan Firms Face Uphill Battle: DPP Exec
November 28, 2024
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…